No Data
No Data
Hong Kong stocks soar | Hutchmed (China) (00013) rises over 5% again. The company has recently introduced progress in innovative drugs. Institutions say that research and development progress is rapid.
Hutchmed (China) (00013) rose more than 5%, as of publication, up 5.41%, reported at HKD 31.2, with a turnover of HKD 44.2823 million.
China Securities Co.,Ltd: Accelerating development of the self-immunity market to promote the improvement and efficiency of the domestic innovative drug industry.
The patient population with autoimmune diseases and type II inflammation is growing rapidly, the market size is second only to cancer drugs, but still in a period of accelerated development. Existing drugs still have huge room for improvement in efficacy and safety.
Hutchmed (China) (0013.HK): Introduces progress of innovative drug development on R&D day. The core pipeline has great market potential.
Company Event: On July 9th, Hutchmed (China) held its 2024 R&D Day exchange activities, in which the company's management team focused on sharing clinical data and market value of candidate innovation pipelines, including clinical data of surufatinib in autoimmune diseases.
U.S. stock abnormality | Northeast securities maintains a "buy" rating, and hutchmed (china) (HCM.US) rose more than 8%.
As of press time, the stock has risen over 8% to $19.245.
U.S. Stocks surged: brokerage optimistic about hutchmed (china), pre-market trading boosted by 4%; Listed in Hong Kong saw a significant increase of over 7% today.
On July 12th, Hutchmed (China) gained over 7% in Hong Kong stocks, leading to a pre-market trading increase of 4% for HCM.US, with a price of $8.5. Northeast Securities' research reports indicate that the company has made rapid development in recent R&D, with multiple products launched simultaneously, demonstrating excellent clinical data and competitive landscape. The company is continuously promoting its products globally, and is expected to continue to catalyze the value of the company's fundamentals. In addition, the company has abundant pipeline reserves and a broad product market space, continuously achieving overseas release. Maintain a 'buy' rating on the company.
Mid-day overview: Hong Kong stocks are consolidating with the Hang Seng Index up nearly 2%; Mainland real estate is booming with Shimao Group up more than 14%.
Network technology rose, JD.com Group rose more than 4%, Meituan, Alibaba, Tencent Holdings, and Kuaishou all rose more than 2%.
No Data